Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: AZD7760 in Healthy Participants and ESKD Patients on Hemodialysis
NCT06749457Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD7760 in Staphylococcus aureus infection (7 arms), sponsored by AstraZeneca. Primary endpoints: Occurrence of adverse events at Day 361 and Occurrence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) at Day 451. Started Dec 2024; status: active, not recruiting.
02
Drugs
AZD7760
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT06749457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749457.